Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo
The DOI matches its Crossref record.
Abstract
OBJECTIVE: A 26-week, double-blind, placebo-controlled relapse prevention study of aripiprazole was designed a priori with a prospective, 74-week, double-blind, placebo-controlled extension phase. Efficacy and tolerability of aripiprazole for relapse prevention in bipolar I disorder was, therefore, evaluated for 100 weeks. METHOD: Patients with DSM-IV bipolar I disorder, recent manic or mixed episode, received open-label aripiprazole 15 or 30 mg/day (started at 30 mg/day) for 6 to 18 weeks. Patients achieving stabilization (Young Mania Rating Scale score or= 5% incidence and twice placebo rate) were tremor, akathisia, dry mouth, hypertension, weight gain, vaginitis, abnormal thinking, pharyngitis, and flu syndrome. Mean weight change from baseline to 100 weeks (last observation carried forward) was +0.4 +/- 0.8 kg with aripiprazole and -1.9 +/- 0.8 kg with placebo. CONCLUSIONS: Over a 100-week treatment period, aripiprazole monotherapy was effective for relapse prevention in patients who were initially stabilized on aripiprazole for 6 consecutive weeks, and it maintained a good safety and tolerability profile. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00036348.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“aripiprazole oral (level 2)375, 376 or once monthly (level 2)377 is also recommended as a first‐line monotherapy in view of its efficacy in preventing any mood or manic episode as well as its safety/tolerability profile, although it has not been shown to be effective in preventing depression.”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Yatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
Self-citationAlmost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Goodwin, G., & Consensus Group of the British Association for Psychopharmacology (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109102919 · Cited by 444
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Vieta, E., Suppes, T., Eggens, I., Persson, I., Paulsson, B., & Brecher, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.001 · Cited by 227
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.015 · Cited by 200
Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder
Popovic, D., Reinares, M., Goikolea, J. M., Bonnin, C. M., Gonzalez-Pinto, A., & Vieta, E. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.008 · Cited by 187
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“…an acute mixed episode in preventing episodes of any polarity or a new manic, depressive or mixed episode For the 48 patients with mixed index episodes participating in the aripiprazole oral continuation studies (Keck et al. 2006; Keck et al. 2007), no separate outcome data have been reported.”
BackgroundTreatment of bipolar disorder: a systematic review of available data and clinical perspectives
Fountoulakis, K. N., & Vieta, E. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009231 · Cited by 169
Diagnosis and management of bipolar disorders
Goes, F. S. (2023) · BMJ · doi:10.1136/bmj-2022-073591 · Cited by 205
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00946-6 · Cited by 169
Keck, P. E., Orsulak, P. J., Cutler, A. J., Sanchez, R., Torbeyns, A., Marcus, R. N., McQuade, R. D., & Carson, W. H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.05.014 · Cited by 172
Self-citationVieta, E., T’joen, C., McQuade, R. D., Carson, W. H., Marcus, R. N., Sanchez, R., Owen, R., & Nameche, L. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07101560 · Cited by 161
Why antidepressants are not antidepressants: STEP‐BD, STAR*D, and the return of neurotic depression
Nassir Ghaemi, S. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00639.x · Cited by 144
A review of valproate in psychiatric practice
Haddad, P. M., Das, A., Ashfaq, M., & Wieck, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902911455 · Cited by 134
Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., Perry, P., Hertel, P., Such, P., Salzman, P. M., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11201 · Cited by 135
Self-citationEfficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Fountoulakis, K. Ν., Kasper, S. F., Andreassen, O. A., Blier, P., Okasha, A., Severus, E., Versiani, M., Tandon, R., Möller, H., & Vieta, E. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0323-x · Cited by 149
Management of antipsychotic-related weight gain
Maayan, L., & Correll, C. U. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.85 · Cited by 128
Marcus, R., Khan, A., Rollin, L., Morris, B., Timko, K., Carson, W., & Sanchez, R. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00898.x · Cited by 130
Clinical practice recommendations for bipolar disorder
Malhi, G. S., Adams, D., Lampe, L., Paton, M., O’Connor, N., Newton, L. A., Walter, G., Taylor, A., Porter, R., Mulder, R. T., et al. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01383.x · Cited by 129
Lindström, L., Lindström, E., Nilsson, M., & Höistad, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.012 · Cited by 122
Findling, R. L., Correll, C. U., Nyilas, M., Forbes, R. A., McQuade, R. D., Jin, N., Ivanova, S., Mankoski, R., Carson, W. H., & Carlson, G. A. (2013) · Bipolar Disorders · doi:10.1111/bdi.12042 · Cited by 121
Fountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
Aripiprazole in schizophrenia and schizoaffective disorder: A review
Stip, É., & Tourjman, V. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.01.021 · Cited by 127
Vieta, E., Günther, O., Locklear, J., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000885 · Cited by 106
Young, A. H., Oren, D. A., Lowy, A., McQuade, R. D., Marcus, R. N., Carson, W. H., Spiller, N. H., Torbeyns, A. F., & Sanchez, R. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.049965 · Cited by 109
Popovic, D., Torrent, C., Goikolea, J. M., Cruz, N., Sánchez‐Moreno, J., González‐Pinto, A., & Vieta, E. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12179 · Cited by 101
Vázquez, G. H., Holtzman, J. N., Lolich, M., Ketter, T. A., & Baldessarini, R. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.013 · Cited by 102
“Recurrences averaged 30.3%/year with placebo, ranging from 21.7 (Keck et al., 2007) to 40.9 %/year (Bowden et al., 2003), with strong separation of active treatments from placebo in the six trials that included a placebo condition (Table 4; Figure 1).”
InfluentialBerwaerts, J., Melkote, R., Nuamah, I., & Lim, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.047 · Cited by 101
Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis
Vieta, E., & Valentí, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0073-y · Cited by 106
Nestsiarovich, A., Gaudiot, C., Baldessarini, R. J., Vieta, E., Zhu, Y., & Tohen, M. F. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.08.264 · Cited by 107
Aripiprazole: from pharmacological profile to clinical use
Riva, M. A., & Sciascio, G. D. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s88117 · Cited by 97
Nolen, W. A., & Weisler, R. H. (2013) · Bipolar Disorders · doi:10.1111/bdi.12027 · Cited by 73
Maintenance therapies in bipolar disorders
Gitlin, M., & Frye, M. A. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.00992.x · Cited by 70
Managing the side effects associated with commonly used treatments for bipolar depression
Kemp, D. E. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70007-2 · Cited by 62
Treatment Implications of Predominant Polarity and the Polarity Index: A Comprehensive Review
Carvalho, A. F., Quevedo, J., McIntyre, R. S., Soeiro-de-Souza, M. G., Fountoulakis, K. N., Berk, M., Hyphantis, T. N., & Vieta, E. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu079 · Cited by 66
Lithium Therapy and Hyperparathyroidism: An Evidence‐Based Assessment
Saunders, B., Saunders, E. F. H., & Gauger, P. G. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-9942-4 · Cited by 75
Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012
Kanba, S., Kato, T., Terao, T., Yamada, K., & Committee for Treatment Guidelines of Mood Disorders, J. S. O. M. D. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12060 · Cited by 68
Szegedi, A., Durgam, S., Mackle, M., Yu, S. Y., Wu, X., Mathews, M., & Landbloom, R. P. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16040419 · Cited by 66
Carlson, B. X., Ketter, T. A., Sun, W., Timko, K., McQuade, R. D., Sanchez, R., Vester‐Blokland, E., & Marcus, R. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00974.x · Cited by 63
Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice
Coryell, W. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00712.x · Cited by 64
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Mohr, P., Masopust, J., & Kopeček, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.781946 · Cited by 69
Gentile, S. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00589.x · Cited by 61
Using Lithium in Older Age Bipolar Disorder: Special Considerations
Soh, J. F., Klil‐Drori, S., & Rej, S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-0628-1 · Cited by 63
Beynon, S., Soares-Weiser, K., Woolacott, N., Duffy, S., & Geddes, Jr. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093885 · Cited by 61
Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients
Mazza, M., Squillacioti, M. R., Pecora, R. D., Janiri, L., & Bria, P. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2008.05.003 · Cited by 60
Malhi, G. S., Adams, D., Cahill, C. M., Dodd, S., & Berk, M. (2009) · Drugs · doi:10.2165/11318850-000000000-00000 · Cited by 64
Medicating mood with maintenance in mind: bipolar depression pharmacotherapy
Malhi, G. S., Adams, D., & Berk, M. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00711.x · Cited by 59
Findling, R. L., Kauffman, R. E., Sallee, F. R., Salazar, D. E., Sahasrabudhe, V., Kollia, G. D., Kornhauser, D. M., Vachharajani, N. N., Assunção-Talbott, S., Mallikaarjun, S., et al. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0111 · Cited by 60
Aripiprazole monotherapy in the treatment of bipolar disorder: A meta-analysis
Fountoulakis, K. N., Vieta, E., & Schmidt, F. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.10.018 · Cited by 52
Das, C., Mendez, G., Jagasia, S., & Labbate, L. A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400306 · Cited by 52
Muzina, D. J., Momah, C., Eudicone, J. M., Pikalov, A., McQuade, R. D., Marcus, R. N., Sanchez, R., & Carlson, B. X. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01735.x · Cited by 52
Vieta, E., Owen, R., Baudelet, C., McQuade, R. D., Sanchez, R., & Marcus, R. N. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003779380 · Cited by 53
Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder
Popović, D., Reinares, M., Amann, B. L., Salamero, M., & Vieta, E. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2056-8 · Cited by 52
Application of Antipsychotic Drugs in Mood Disorders
RYBAKOWSKI, J. K. (2023) · Brain Sciences · doi:10.3390/brainsci13030414 · Cited by 57
A review of the safety and tolerability of aripiprazole
Pae, C. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902835493 · Cited by 52
A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder
Yatham, L. N. (2011) · Journal of Affective Disorders · doi:10.1016/s0165-0327(11)70005-2 · Cited by 51
Kishi, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021) · Psychological Medicine · doi:10.1017/s0033291720003505 · Cited by 48
Singh, M. K., Ketter, T. A., & Chang, K. (2010) · Drugs · doi:10.2165/11534540-000000000-00000 · Cited by 48
Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?
Yalın, N., & Young, A. H. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s245166 · Cited by 54
Pacchiarotti, I., Anmella, G., Colomer, L., & Vieta, E. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13209 · Cited by 51
Bushe, C. J., Slooff, C. J., Haddad, P. M., & Karagianis, J. L. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112473789 · Cited by 45
Young, A. H., McElroy, S. L., Olausson, B., Paulsson, B., (D1447C00001), O. B. O. T. E. I., & Embolden II (D1447C00134) Investigators (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.665177 · Cited by 46
Maintenance Pharmacological Treatment of Juvenile Bipolar Disorder: Review and Meta-Analyses
Yee, C. S., Hawken, E. R., Baldessarini, R. J., & Vázquez, G. H. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz034 · Cited by 48
Mallakh, R. S. E., Vieta, E., Rollin, L., Marcus, R. N., Carson, W. H., & McQuade, R. D. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.003 · Cited by 48
The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review
Muneer, A. (2016) · Cureus · doi:10.7759/cureus.562 · Cited by 52
Yatham, L. N., Fountoulakis, K. Ν., Rahman, Z. U., Ammerman, D., Fyans, P., Marler, S. V., Baker, R. A., & Carlson, B. X. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.042 · Cited by 45
Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis
Speyer, H., Westergaard, C., Albert, N., Karlsen, M., Stürup, A. E., Nordentoft, M., & Krogh, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.577919 · Cited by 44
Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review
Fountoulakis, K. Ν., & Vieta, E. (2009) · Annals of General Psychiatry · doi:10.1186/1744-859x-8-16 · Cited by 46
Tsai, A. C., Rosenlicht, N. Z., Jureidini, J. N., Parry, P. I., Spielmans, G. I., & Healy, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000434 · Cited by 43
Rating Scales in Bipolar Disorder
Sajatovic, M., Chen, P., & Young, R. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-405170-6.00009-9 · Cited by 57
Aripiprazole: A Review of its Use in the Management of Mania in Adults with Bipolar I Disorder
Dhillon, S. (2011) · Drugs · doi:10.2165/11208320-000000000-00000 · Cited by 44
Aripiprazole: Dose-Response Relationship in Schizophrenia and Schizoaffective Disorder
Mace, S., & Taylor, D. M. (2009) · CNS Drugs · doi:10.2165/11310820-000000000-00000 · Cited by 44
Quante, A., Zeugmann, S., Luborzewski, A., Schommer, N. C., Langosch, J. M., Born, C., Anghelescu, I. G., & Wolf, J. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1096 · Cited by 45
Prescribing Patterns for Treatment of Pediatric Bipolar Disorder in a Specialty Clinic
Potter, M. P., Liu, H. Y., Monuteaux, M. C., Henderson, C. S., Wozniak, J. R., Wilens, T. E., & Biederman, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0142 · Cited by 38
Vieta, E., Suppes, T., Ekholm, B., Udd, M., & Gustafsson, U. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.014 · Cited by 37
Woo, Y. S., Bahk, W., Chung, M. Y., Kim, D., Yoon, B., Lee, J. H., Ahn, Y. M., Chung, S., Kim, J., Lee, K. H., et al. (2011) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1240 · Cited by 38
Fagiolini, A., Frank, E., Axelson, D. A., Birmaher, B., Cheng, Y., Curet, D. E., Friedman, E. S., Gildengers, A. G., Goldstein, T., Grochocinski, V. J., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00700.x · Cited by 36
Kemp, D. E., Calabrese, J. R., Tran, Q.-V., Pikalov, A., Eudicone, J. M., & Baker, R. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05159gre · Cited by 33
Self-citationLi, D., Tseng, P., Stubbs, B., Chu, C., Chang, H.-Y., Vieta, E., Fornaro, M., Carvalho, A. F., Solmi, M., Veronese, N., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.023 · Cited by 38
Katzman, M. A. (2011) · Journal of Affective Disorders · doi:10.1016/s0165-0327(11)70004-0 · Cited by 39
Mood Stabilizers of First and Second Generation
RYBAKOWSKI, J. K. (2023) · Brain Sciences · doi:10.3390/brainsci13050741 · Cited by 37
El‐Mallakh, R. S., Marcus, R. N., Baudelet, C., McQuade, R. D., Carson, W. H., & Owen, R. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.11.043 · Cited by 32
McIntyre, R. S., McElroy, S. L., Eudicone, J. M., Forbes, R. A., Carlson, B. X., & Baker, R. A. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.11m01182 · Cited by 34
Kanba, S., Kawasaki, H., Ishigooka, J., Sakamoto, K., Kinoshita, T., & Kuroki, T. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.669047 · Cited by 31
Evidence review and clinical guidance for the use of ziprasidone in Canada
Gardner, D. M., Murphy, A. L., Kutcher, S., Beaulieu, S., Carandang, C. G., Labelle, A., Lalonde, P., MALLA, A. K., Milliken, H., O’Donovan, C., et al. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-1 · Cited by 32
Kurita, M. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s109835 · Cited by 42
Drug safety evaluation of aripiprazole in bipolar disorder
Cuomo, A., Crescenzi, B. B., Goracci, A., Bolognesi, S., Giordano, N. G., Rossi, R., Facchi, E., Neal, S. M., & Fagiolini, A. M. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1617847 · Cited by 33
Glick, I. D., Mankoski, R. E., Eudicone, J. M., Marcus, R. N., Tran, Q.-V., & Assunção-Talbott, S. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.12.017 · Cited by 32
The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances
Hirschowitz, J., Kolevzon, A., & Garakani, A. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.507042 · Cited by 33
Aripiprazole for the maintenance treatment of bipolar I disorder: A review
McIntyre, R. S. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.01.022 · Cited by 32
Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials
Arbaizar, B., Dierssen‐Sotos, T., Gómez‐Acebo, I., & Llorca, J. (2009) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.05.005 · Cited by 28
Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review
Roosen, L., & Sienaert, P. A. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.017 · Cited by 29
Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J. C., Cox, K., Johnson, B. R., Perry, P. P., Hertel, P., Such, P., McQuade, R. D., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.035 · Cited by 29
Self-citationHeal, D. J., Gosden, J., Jackson, H. C., Cheetham, S. C., & Smith, S. L. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_6 · Cited by 27
Goodwin, F. K., Whitham, E. A., & Ghaemi, S. N. (2011) · CNS Drugs · doi:10.2165/11593740-000000000-00000 · Cited by 34
Korean medication algorithm for bipolar disorder: Second revision
Shin, Y. C., Min, K. J., Yoon, B.-H., Kim, W. K., Jon, D., Seo, J. S., Woo, Y. S., Lee, J. G., & Bahk, W. (2013) · Asia-Pacific Psychiatry · doi:10.1111/appy.12062 · Cited by 27
Metadata
- Authors
- Keck, P. E., & Calabrese, J. R.
- Affiliations
- University of Cincinnati (US)
- ORCID
- Calabrese, Joseph R.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-10-15
- Volume
- 68
- Issue
- 10
- Pages
- 1480-1491
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2087458061
- Cited by
- 238
- References
- 0
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 7 · 2019: 7 · 2018: 8 · 2017: 11 · 2016: 8 · 2015: 10 · 2014: 8 · 2013: 17 · 2012: 25
- FWCI
- 14.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- aripiprazole, bipolar I disorder, relapse prevention, maintenance therapy, monotherapy, manic episodes, mixed states, Young Mania Rating Scale, tolerability, adverse effects, weight change
- MeSH terms
- Aripiprazole, Adult, Bipolar Disorder, Depression, Double-Blind Method, Drug Administration Schedule, Female, Humans, Lorazepam, Male, Piperazines, Prospective Studies, Surveys and Questionnaires, Remission Induction, Severity of Illness Index, Antipsychotic Agents, Quinolones, Prevalence, GABA Modulators, Diagnostic and Statistical Manual of Mental Disorders, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.